Cancer clinical trials in the region Île-de-France

642 currently recruiting clinical trials
Region Île-de-France

Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
B cell lymphoma Large B cell lymphoma Primary mediastinal lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma MALT lymphoma Indolent transformed lymphoma None 2 3 or more Chemotherapy Monoclonal antibodies
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00
B cell lymphoma Large B cell lymphoma Follicular lymphoma Indolent transformed lymphoma None 2 3 or more Chemotherapy Monoclonal antibodies
Systemic Treatment-Naive Car-T
4 recruiting sites
Cellectis SA
Phase 1 / Phase 2 Lymphoma #NCT06495723 #2023-509648-88-00
T cell lymphoma Peripheral T cell lymphoma None 1 2 3 or more Chemotherapy
Systemic Treatment-Naive
5 recruiting sites
Xenothera SAS
Phase 1 / Phase 2 Lymphoma #NCT06090539
B cell lymphoma Large B cell lymphoma Follicular lymphoma Indolent transformed lymphoma None 2 3 or more
Systemic Treatment-Naive Car-T
7 recruiting sites
Bristol-Myers Squibb
Phase 1 / Phase 2 Breast cancer #NCT04626635 #2022-501234-37-00
HER2 Negative HR Negative Locally Advanced Metastatic 1 2 3 or more
Systemic Treatment-Naive
13 recruiting sites
Regeneron Pharmaceuticals
Phase 1 / Phase 2 Lung cancer #NCT06362252 #2023-509629-36-00
SCLC (Small Cell Lung Cancer) Metastatic None Immunotherapy Chemotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome #NCT06542250 #2024-511099-34-00
B cell lymphoma CLL (Chronic Lymphocytic Leukemia) Large B cell lymphoma Mantel cell lymphoma Follicular lymphoma Lymphocytic lymphoma None 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Liver and bile duct cancer #NCT04524871 #2023-506611-17-00
Hepatocellular carcinoma Locally Advanced Metastatic Unhealthy A None Systemic Treatment-Naive
Immunotherapy
2 recruiting sites
Hoffmann-La Roche
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT06637423
Non-invasive bladder cancer Urothelial carcinoma Localized 1 2 3 or more
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06923761 #2023-504845-30-00
Locally Advanced Metastatic MSS/pMMR 1 2 3 or more
Systemic Treatment-Naive
7 recruiting sites
Grey Wolf Therapeutics